Devi's Made Generic APIs and Custom Synthesis APIs

3min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Devi's began with an ingredient for a drug called naproxen, a popular anti-inflammatory drug. It used enzymes instead of chemicals to induce a reaction from the drug faster. Pharma giants knew there was no conflict of interest, unlike other Indian pharma companies. Devi's became a star of the Indian pharma industry and its share price rocketed by a staggering 1000% between 2010 and 2020. But the last 1.5 years have not been kind to the company - shares have crashed by nearly 50%. And more recently, it's a bit dumb margins.

In today's episode for 11th February 2023, we see what's really happening at Divi's laboratories.

We're now on YouTube. But not as Finshots.

Instead, get ready for a fresh perspective on finance with the beloved curator and co-founder of Finshots' - Shrehith Karkera where he deep dives into the world of finance completely unfiltered.

In our latest video, we cover how startup scams happen and explore the dark side of entrepreneurship.

Tune in now to Shrehith Karkera (https://youtube.com/@shrehithskarkera) on YouTube and don’t forget to subscribe to stay ahead of the game in finance.